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Angiogenesis is the formation of new blood vessels from the existing vasculature, and is essential for the growth and
metastasis of most solid tumours. One of the most important growth factors involved in the angiogenesis process is vascular
endothelial growth factor. Vascular endothelial growth factor expression has been shown to be regulated by female hormones
in breast cancer cell lines, and two previous authors have reported on cyclical variations in serum vascular endothelial growth
factor concentrations with conﬂicting results. No work has been performed on variations in plasma levels of vascular
endothelial growth factor during the menstrual cycle. We therefore conducted the ﬁrst prospective trial to compare serum
and plasma levels of vascular endothelial growth factor in healthy pre-menopausal volunteers. Twenty healthy pre-menopausal
women were recruited and had blood samples taken over one menstrual cycle with an average of eight samples taken per
patient. Plasma and serum samples were then analysed for sex hormones and vascular endothelial growth factor 165. Serum
vascular endothelial growth factor levels were found to be signiﬁcantly higher than plasma vascular endothelial growth factor
levels (P50.005). We found no signiﬁcant difference between serum and plasma vascular endothelial growth factor in the
luteal and follicular phases of the cycle. The majority of the measurements for plasma levels of vascular endothelial growth
factor at all phases of the cycle were under the limit of detection of the vascular endothelial growth factor ELISA kit. We
found no signiﬁcant correlation between plasma or serum levels of vascular endothelial growth factor and either FSH, LH,
Oestradiol or Progesterone levels. This study has demonstrated no difference in serum concentrations of vascular endothelial
growth factor during the different phases of the menstrual cycle in a group of healthy volunteers. We also demonstrated no
obvious difference in plasma concentrations of vascular endothelial growth factor between the phases of the cycle, but most
of the measurements were below the level of accuracy reported by the ELISA kit manufacturer. With the sensitivity of this
ELISA test, therefore, we must still regard the question of whether there is a variation in plasma concentrations of vascular
endothelial growth factor throughout the menstrual cycle as unanswered.
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Angiogenesis is the formation of new blood vessels from the
existing vasculature, and is essential for the growth and metasta-
sis of many solid tumours (Folkman, 1990), including breast
cancer (Weidner, 1991). The degree of angiogenesis of a tumour
is directly related to the aggressiveness of the tumour, and serves
as an independent prognostic factor in breast cancer (Bosari,
1992). One of the most important growth factors involved in
the angiogenesis process is vascular endothelial growth factor
(VEGF). VEGF induces endothelial cell proliferation and it plays
a vital role in regulating both physiologic and pathological
angiogenesis. VEGF is a heparin binding glycoprotein that is
secreted as a homodimer of 45 kDa. Most types of cells, but
usually not endothelial cells themselves, secrete VEGF. VEGF
can also stimulate cell migration and inhibit apoptosis. Expres-
sion of VEGF in breast tumours correlates directly with the
degree of angiogenesis of the tumour, and is an independent
indicator of nodal metastases and disease free survival (Hitoshi,
1996; Obermair, 1997).
In addition to being upregulated within tumours, various
growth factors and angiogenic cytokines, including VEGF, have
been demonstrated in the sera and other body ﬂuids of patients
with a wide variety of cancers (Yamamoto, 1996). In breast cancer
serum levels of VEGF have been shown to rise with increasing stage
of disease, and in colorectal cancer serum VEGF levels have been
used to predict oncological clearance (Kumar et al, 1998).
Vascular endothelial growth factor expression has been shown to
be regulated by female hormones in breast cancer cell lines (Hyder
et al, 1998; Nakamura et al, 1996). It has been hypothesised that
circulating levels of VEGF may alter with the menstrual cycle
and be responsible for the reported increase in recurrence rate in
patients operated on during the follicular phase of the cycle. Two
recent studies have reported on this hypothesis with conﬂicting
results. Heer et al (1998) demonstrated a higher serum level of
VEGF during the follicular phase of the cycle in 14 healthy pre-
menopausal volunteers. Chung et al (1998) however, demonstrated
M
o
l
e
c
u
l
a
r
a
n
d
C
e
l
l
u
l
a
r
P
a
t
h
o
l
o
g
y
Received 2 October 2001; revised 4 March 2002; accepted 27 March 2002
*Correspondence: C McIlhenny; Flat 3/3, 82 Chancellor Street, Glasgow
G11 5PW, UK; E-mail: craig.mcilhenny@ntlworld.com
British Journal of Cancer (2002) 86, 1786–1789
ã 2002 Cancer Research UK All rights reserved 0007–0920/02 $25.00
www.bjcancer.comno signiﬁcant differences in serum VEGF during the two phases of
the cycle again in 14 healthy pre-menopausal volunteers.
Recent work has thrown doubt on the validity of measuring
serum levels of VEGF. Since these studies have been carried out,
it has become apparent that many haematological cells are capable
of releasing VEGF, especially platelets (Banks, 1998). The extent to
which these cells normally contribute to the circulating VEGF pool
in vivo and the physiological relevance of this is not known. The
measurement of serum concentrations of VEGF has therefore been
speculated upon as being an artiﬁcial situation, which measures
both the freely circulating VEGF and that released by platelets
upon activation during the clotting process (Verheul et al, 1997).
Therefore the signiﬁcance of these studies that measure serum
VEGF concentrations remains unclear, and plasma levels of VEGF
may be a more accurate reﬂection of any biologically active circu-
lating angiogenic cytokine. At present we have no information on
the normal plasma concentrations of VEGF or if it varies during
the menstrual cycle.
The aim of our study was to measure serum and plasma concen-
trations of VEGF in a group of healthy pre-menopausal volunteers
and to determine if there is a cyclical variation during the menstru-
al cycle.
MATERIALS AND METHODS
Subjects
Twenty healthy pre-menopausal women with no signiﬁcant past
medical history were recruited to the trial. All had regular menstru-
al cycles and were not taking any form of extrinsic hormones, such
as the oral contraceptive pill. Ethical Committee approval was
sought and obtained for the study and all volunteers gave written
informed consent.
Collection of blood samples
Blood samples were taken from the patients for between 4–6
weeks depending on the length of the menstrual cycle. An average
of eight samples was taken per patient (Range 6–9). These samples
were drawn at 4 day intervals over the course of a single cycle.
Samples were collected using the Vacutainer (Beckton Dickinson,
UK) system, and approximately 20 mL of blood was drawn at each
sampling interval. Samples were collected into three different tubes
for analysis. Glass tubes containing SST Gel and Clot Activator
were used to assay for FSH, LH, Oestradiol and Progesterone. Plas-
ma samples were collected in glass tubes containing EDTA as an
anticoagulant and were spun down at 10000 r.p.m. for 10 min
and then frozen at 7708C within 20 min of collection, pending
analysis for VEGF. Serum samples were collected in plain glass
tubes and allowed to coagulate for 60 min prior to spinning down
and freezing at 7708C, again pending analysis for VEGF.
VEGF determination
Plasma and serum samples were analysed for VEGF using a
commercially available sandwich enzyme linked immunosorbent
assay (ELISA) that was obtained from R&D Systems Europe,
Abingdon UK (Quantikine Human VEGF). This kit has been used
in many previous studies and has a low inter- and intra-assay error
range (Intra-assay Error: 6.7–4.5 CV% in Serum/Plasma, Inter-
assay Error: 8.8–6.2 CV% in Serum/Plasma). This assay is speciﬁc
for VEGF and does not detect related molecules such as platelet
derived growth factor or placental growth factor.
Brieﬂy, a monoclonal antibody speciﬁc for VEGF 165 has been
precoated onto the supplied microplate wells. Standards and
samples are pipetted into the wells and the immobilised antibody
binds any VEGF present. After washing away any unbound
substances, an enzyme-linked polyclonal antibody speciﬁc for
VEGF 165 is added to the wells. Following a further wash to
remove unbound substance, a substrate solution is added to the
wells and colour develops in proportion to the amount of VEGF
bound in the initial step. The colour development is stopped after
a speciﬁed time period with stop solution and the intensity of the
colour is measured. A standard curve is constructed using supplied
VEGF standards. All samples were assayed in duplicate and read-
ings were made on a Dynatech MR5000 micro-plate reader with
the test ﬁlter set at 450 nm and correction wavelength set at
570 nm, to account for optical imperfections in the plate. The
sensitivity of the assay is 9.0 pg ml
71 as quoted by the manufac-
turer.
Hormone determination
Samples were analysed using an automated Bio-Immuno-1 analy-
ser, which gives direct readouts for FSH, LH, Oestradiol and
Progesterone levels in serum.
Determination of menstrual phases
Menstrual cycles for each patient were divided into follicular and
luteal phases on the basis of the last recalled onset of menses,
the actual date of menses during the study period, and an observed
LH peak followed by a progesterone level that fell to within the
luteal phase values of the assay used.
Statistical analysis
The signiﬁcance between VEGF concentrations, oestradiol and
progesterone levels of the two phases of the menstrual cycle was
calculated using the Mann–Whitney U-test for non-parametric
data. Spearman’s Correlation between the variables was also calcu-
lated. Statistical signiﬁcance was set at a P value of less than 0.05.
Calculations were performed using SPSS for Windows Version
7.5.1 (SPSS inc.).
RESULTS
The median age of the enrolled volunteers was 36.3 years (range
28–47). The length of the menstrual cycles varied from 23–34
days with a mean cycle length of 27.8 days. All cycles were found
to be ovulatory, as witnessed by an LH peak followed by an appro-
priate mid-luteal peak in progesterone levels.
Progesterone levels were signiﬁcantly higher in the luteal phase
of the cycle than in the follicular phase of the cycle (P50.005),
which would be consistent with the expected normal ovulatory
luteal function. Oestradiol levels were signiﬁcantly higher during
the follicular phase of the menstrual cycle (P50.005), and again
these values correspond to the expected range of oestradiol in
ovulatory cycles.
Serum VEGF levels were found to be signiﬁcantly higher than
plasma VEGF levels. The median value for serum VEGF through-
out the cycle was 261.13 pg ml
71 (range 6.01–774.76, Standard
Deviation 159.6) whereas the median value for plasma concentra-
tion of VEGF was 5.78 pg ml
71 (range 0.0 to 70.72, Standard
Deviation 13.47), although these values for plasma are below the
sensitivity of the ELISA kit as quoted by the manufacturer (sensi-
tivity=9.0 pg ml
71). This difference was statistically signiﬁcant
with a P-value of less than 0.005 using the two-tailed Mann–Whit-
ney U-test. The majority of the measurements for plasma levels of
VEGF at all phases of the cycle were under the limit of detection of
the VEGF ELISA kit.
Samples were redeﬁned into luteal and follicular phases based on
an observed LH peak and re-analysed. We found no signiﬁcant
difference between either serum or plasma levels of VEGF in the
luteal and follicular phases of the cycle (Wilcoxon Sign Rank test
P=0.267 for serum levels and P=0.424 for plasma levels). With
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phase was 268.8 (range 12.23–693.37, 95% Conﬁdence interval
39.9). Mean level of serum VEGF during the follicular phase of
the cycle was 286.66 (range 6.01–774.76, 95% Conﬁdence Interval
38.97) (Figure 1). We found no signiﬁcant correlation between
either plasma or serum levels of VEGF and either FSH, LH, Oestra-
diol or Progesterone levels using Spearman’s correlation.
DISCUSSION
Angiogenesis is essential for tumour growth and metastasis (Folk-
man, 1990). The angiogenic process is complex and is regulated
by a wide variety of growth factors, both positive and negative.
Vascular Endothelial Growth Factor (VEGF) is a potent and widely
distributed angiogenic peptide, which has been widely implicated
in tumour progression. This growth factor is a dimeric 34–42
Kd glycosylated basic protein, which is encoded in four molecular
isoforms. The two larger isoforms (VEGF 189 and VEGF 209)
remain cell associated whereas the smaller isoforms (VEGF 121
and VEGF 165) are secreted as soluble molecules. The latter
isoforms induce their angiogenic effects by binding to the speciﬁc
transmembrane tyrosine kinase receptors KDR/Flk-1 and Flt-1,
which are selectively expressed on vascular endothelial cells. Higher
expression of VEGF and its receptors in breast tumours has been
shown to be signiﬁcantly associated with high intra-tumoural
micro-vessel density and also with poorer prognosis (Weidner,
1991; Bosari, 1992).
In addition to being upregulated within tumours, levels of
angiogenic cytokines have been reported to be increased in the
serum and other body ﬂuids of patients with cancer (Yamamoto,
1996). In breast cancer patients, higher levels of serum VEGF have
been demonstrated in patients with stage III as compared to stage I
or stage II disease (Yamamoto, 1996).
While the signiﬁcance of circulating levels of VEGF in cancer
patients is now being elucidated, the signiﬁcance of circulating
VEGF levels in healthy volunteers is unclear. Serum levels of VEGF
have been reported to be higher in post-menopausal volunteers
than in pre-menopausal women (Heer et al, 1998) with a mean
of 243.9 pg ml
71 (InterQuartile range 128.5–425.6) in post-meno-
pausal women vs a mean of 165.0 pg ml
71 (IQR 88.2–236.3) in
pre-menopausal women. This author also reported a signiﬁcant
difference in serum levels of VEGF between the two phases of
the menstrual cycle in 14 healthy volunteers. A median value of
VEGF during the luteal phase of 174.7 pg ml
71 was signiﬁcantly
lower than a level of 206.5 pg ml
71 (P=0.03).
Heer et al (1998) hypothesised that any possible survival advan-
tage (reported by authors such as Badwe et al (1991) of patients
who undergo breast cancer surgery in the luteal phase of the cycle
could be due to this difference in serum levels of VEGF found in
his study. However, Chung (1998), who also measured serum
concentrations of VEGF in 14 healthy pre-menopausal volunteers,
carried out a similar study. This study demonstrated no difference
in serum VEGF concentrations between the two phases of the cycle.
Workers such as Banks demonstrated more recently that VEGF
is contained in platelets and that this should be taken into account
when measuring circulating VEGF concentrations. It is now appar-
ent that many haematological cells are capable of releasing VEGF
(Banks, 1998; Webb et al, 1998; Mohle et al, 1997). The extent
to which these cells normally contribute to the circulating VEGF
pool in vivo and the physiological relevance of this is not known.
The measurement of serum concentrations of VEGF has therefore
been speculated upon as being an artiﬁcial situation, which
measures both the freely circulating VEGF and that released mainly
by platelets upon activation during the clotting process. The actual
act of collecting serum samples causes platelet activation, and
release of large amounts of VEGF from the alpha granules
contained within the platelets. It therefore remains unclear which
measurement of circulating VEGF actually represents the true
amount of biologically active VEGF in the circulation.
With respect to our study, we recruited 20 healthy pre-meno-
pausal volunteers, and followed them for one menstrual cycle.
This study is the largest to date, with both previous similar studies
having only 14 patients enrolled. In our study both plasma and
serum samples were collected, and this is therefore the ﬁrst study
to report on plasma values of VEGF during the menstrual cycle.
Menstrual phase was assessed by reviewing hormonal proﬁles.
We found all cycles to be ovulatory in our group of volunteers.
Normal hormonal patterns were also found. However we found
no signiﬁcant difference between phases of the menstrual cycle with
respect to either serum or plasma concentrations of VEGF. The
mean concentration of VEGF, which we found in serum, was
261.13 pg ml
71. This value is higher than the values quoted by
Heer et al (1998) for both pre- and post-menopausal women
(165 pg ml
71 and 243.9 pg ml
71 respectively). It is possible that
this difference could be accounted for by a population difference,
but we suspect that differences in sample collection is a more likely
reason. In his study, Heer et al (1998) makes no mention of how
samples were collected or his method for serum separation.
Because we were measuring both serum and plasma samples, we
were extremely vigilant in our sample collection. All samples were
collected by identical means, and serum samples were allowed to
clot for 60 min to ensure thorough platelet activation before centri-
fugation and freezing. This alone may account for our higher value
for serum concentration of VEGF, although in addition, Heer et al
(1998) only utilised three post-menopausal controls, and so we
doubt that this sample can be relied upon to represent the popula-
tion median. Other studies have quoted serum levels of VEGF in
control populations to be similar to ours (Verheul et al, 1997;
Webb et al, 1998), and these studies used similar sample collection
protocols.
Plasma concentrations of VEGF in this study were much lower
than serum concentrations (mean of 261 vs 5.8 pg ml
71), as would
be expected if VEGF released from platelets contributes most of the
VEGF concentration found in a sample of serum. Most of the plas-
ma concentrations measured were below the quoted range of the
ELISA kit (9 pg ml
71). These values are lower than previously
quoted in previous studies quoting population concentrations of
VEGF in plasma (46.4 pg ml
71 by Webb et al, 1998). Once more,
the most likely reason for this was our meticulous collection meth-
od, which was designed to minimise platelet activation. A previous
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over plastic tubes to minimise platelet activation and this was
borne in mind when our protocol was devised. In addition, the
young age of our sample population could account for some differ-
ence. Vascular endothelial growth factor concentrations can be
raised by all manner of pathological processes from trauma to liver
disease to pre-eclampsia (Iitaka et al, 1998; Akiyoshi et al, 1998;
Baker et al, 1995; Grad et al, 1998). In a population with an older
mean age, you could reasonably expect to ﬁnd a cross section of
pathology that is not present in our study population, thus giving
our lower plasma concentrations.
This study has demonstrated no difference in serum concentra-
tions of VEGF during the different phases of the menstrual cycle in
a group of healthy volunteers. We also demonstrated no obvious
difference in plasma concentrations of VEGF between the phases
of the cycle, but most of the measurements were below the level
of accuracy reported by the ELISA kit manufacturer. With the
sensitivity of this ELISA test, therefore, we must still regard the
question of whether there is a variation in plasma concentrations
of VEGF throughout the menstrual cycle as unanswered.
At present, therefore, there is no evidence to suggest that circu-
lating levels of vascular endothelial growth factor vary with the
phase of the menstrual cycle in healthy pre-menopausal women.
We have conﬁrmed that serum concentrations of VEGF are signif-
icantly higher than plasma concentrations, and that most of the
plasma measurements are below the limit of the commercially
available kit that we used.
Based on our results, we conclude that serum concentrations of
VEGF do not vary with the menstrual cycle in healthy volunteers.
Therefore if circulating VEGF were to be utilised in the future for a
tumour marker, then timing of samples will not have to be altered
to take menstrual phase into account. Variations in plasma VEGF
may vary with the phase of the menstrual cycle, but most of the
measurements in healthy volunteers are under the limit of detec-
tion of our ELISA, so we would have to regard this question as
unanswered.
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